Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

93.92USD
25 Apr 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$93.92
Open
--
Day's High
--
Day's Low
--
Volume
221
Avg. Vol
2,978,615
52-wk High
$95.42
52-wk Low
$58.61

Select another date:

Fri, Apr 12 2019

Photo

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion (56.6 billion pounds) acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

UPDATE 2-Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK, April 12 Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK, April 12 Bristol-Myers Squibb Inc's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

UPDATE 5-Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK, March 29 Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

Starboard no longer urging investors to vote against Bristol-Celgene deal

BOSTON Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

UPDATE 1-Starboard no longer urging investors to vote against Bristol-Celgene deal

BOSTON, March 29 Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

Starboard no longer urging investors to vote against Bristol-Celgene deal

BOSTON, March 29 Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

Select another date: